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Stimulating authentic community involvement in
biotechnology policy in Australia
Renato Schibeci and Jeffrey Harwood
This paper analyzes community involvement in biotechnology policy in
Australia. Specifically, we examine the Gene Technology Act 2000 that gov-
erns gene technology in Australia and the roles of the Office of the Gene
Technology Regulator and the Gene Technology Community Consultative
Committee. We contend that the institutions that underpin biotechnology pol-
icy serve to hamper community involvement and reinforce a cognitive deficit
model of community involvement. Finally, we propose how the situation could
be turned around so that interested citizens can participate in authentic com-
munity involvement in biotechnology policy in Australia.
1. Introduction
The idea that community involvement can stimulate trust in government and contribute to more
effective public policy has been a cornerstone of studies of the public understanding of science
over the past decade. Traditionally, policymakers have held that ordinary members of the com-
munity need more information to remedy their lack of understanding, that is, their “deficit”
(Wynne, 1991), and that it is the responsibility of scientists and policymakers to rectify this
“ignorance.” Recent studies have shown, however, that many people now realize that scientific
issues are often clouded in uncertainty and value judgments; hence, they distrust policy
research that privileges scientific knowledge at the expense of their local knowledge and val-
ues (Bush et al., 2001; Fischer, 2002; Gutteling et al., 2006; Jasanoff, 1997; Macoubrie, 2006;
Poortinga et al., 2004; Rowe et al., 2006; Shaw, 2002; Taylor-Gooby, 2006).
This has stimulated the use of focus groups, citizens’ juries, consensus conferences and
the like—what are broadly termed deliberative inclusionary processes (DIPs)—in a variety of
contexts. In their study of the UK National Consensus Conference on Plant Technology, Joss
and Durant (1995: 202) found that it succeeded in stimulating “dialogue between laypeople
and experts.” Moreover, Einsiedel et al. (2001: 94) concluded that the consensus model that
originated in the United States and was adapted by the Danish Board of Technology is trans-
ferable to other political environments—in this case, to Canada and Australia. However, Irwin
(2001) repeatedly observed in the case of the Public Consultation on Developments in the
Biosciences that the deficit model could prevail in cases where the organizers seek to impart
knowledge, rather than create a mutual understanding between the participants. In her analy-
sis of the New Zealand consensus conference on plant biotechnology, Govern (2003: 436–7)
noted that if consensus conferences are not properly organized, they can effectively exclude
views contrary to the prevailing paradigm. Despite these mixed findings and difficulties in
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establishing an agreed basis for the evaluation of DIPs (Rowe et al., 2005), DIPs continue to
be applied to tackle issues in science and technology throughout the world because of their
potential to stimulate mutual understanding between “experts” and “lay publics” and legit-
imize public policy.
The culture of Australian science and technology policy appears to be underpinned by
a cognitive deficit model. This is evident in Parsons’ (2001) discussion of the Parliamentary
Information Program initiated by the Australian government funded Commonwealth
Scientific and Industrial Research Organisation (CSIRO). As the program was intended to
generate a continuing mutual dialogue between scientists and politicians, it was not entirely
congruent with the cognitive deficit model. Nevertheless, there is little indication that the
community has a serious role to play in addressing policy problems. Instead, the CSIRO is
presented as an agency concerned more with transferring knowledge to politicians than
engaging in a two-way dialogue with the community. Parsons (2001: 306–7) explained that
the CSIRO provided “a multifaceted program of information delivery to politicians,” which
includes customized packages e-mailed to all politicians that can be used for policy for-
mulation, speeches, press releases and to help deal with queries from the public. At
Parliament House, “national science briefings” are held that show “how science can pro-
vide solutions to many problems facing Australians and Australian industry” (Parsons,
2001: 307).
In their study of Australian biotechnology policy, Dietrich and Schibeci (2003: 386–7)
found that the cognitive deficit model prevailed amongst biotechnology policymakers in
particular. Indeed, the lead agency, Biotechnology Australia (1999, 2001), used public
opinion surveys to legitimate government policy and reinforce the construction of “the
public” as consumers with a “cognitive deficit.” Furthermore, Dietrich and Schibeci argued
that the authors and proponents of these surveys mistakenly assume a unified public and
ignore the local knowledge possessed by “the public.” To stimulate community involvement
in biotechnology policy, they suggested activities for the Australian government regulatory
agency, the Office of the Gene Technology Regulator (OGTR) and its subcommittee, the
Gene Technology Community Consultative Committee (GTCCC), which they assumed
would become a “conduit of public opinion and participation” (Dietrich and Schibeci,
2003: 397).
In this paper, we continue Dietrich and Schibeci’s work by analyzing the structural fac-
tors that might help or hinder community involvement in Australian biotechnology policy.
First, we examined the work of the OGTR and its supporting committees—the Gene
Technology Technical Advisory Committee, the Gene Technology Ethics Committee and the
Gene Technology Community Consultative Committee—to determine whether there were
any legislative requirements to involve the community. Second, we tracked the work of the
committee given the task of reviewing the Gene Technology Act 2000. Third, we examined
the review of the operations of the Office of the Gene Technology Regulator by the Australian
National Audit Office.
We contend that the failure (or inability) of government agencies to stimulate authen-
tic community involvement in gene technology is due, at least in some part, to institutional
design. In the words of Goodin (1996: 13), “What people want to do, and what they can do,
depends importantly on what organizational technology is available or can be made readily
available to them for giving effect to the individual and collective volitions.” That is, insti-
tutions, such as Parliament, committees, public hearings, citizen juries, and the formal and
informal rules that govern participation in these institutions, matter because they affect the
way that people perceive themselves, their relative position in the political arena and their
opportunities to affect political and policy outputs. This is not to deny the possibility of
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individual free will to act politically; rather, institutions and their associated “rules of the
game” can reinforce predispositions and self-images of people as consumers of informa-
tion, rather than as active citizens.
Hence, we begin this article by setting out the institutional framework for gene tech-
nology policy in Australia. The Gene Technology Act 2000 established the OGTR as the
agency primarily responsible for regulating gene technology and the GTCCC as the com-
mittee responsible for community involvement. In the third part, we explain how the Act
consigns the GTCCC to a minor role compared with the Gene Technology Technical
Advisory Committee, contend that the OGTR has shown little interest in community
involvement and argue that the GTCCC has been constrained by operating procedures that
prevent it from acting to further community involvement. In the fourth part of the article, we
highlight this disinterest in community involvement by critically reviewing a public hearing
that was held in Perth, in October 2005, as part of the review of the Gene Technology Act
2000. In the fifth part, we summarize the findings of the audit conducted by the Australian
National Audit Office in 2004–5 to show how institutional design, notably the Gene
Technology Act 2000, not only affects how the management of the OGTR is audited, but
also limits the attention paid to community involvement in biotechnology. Finally, we pre-
sent a series of amendments to the institutional framework that, if adopted, would likely
stimulate community involvement in Australian biotechnology policy and legitimize the
government’s policies.
2. The institutional framework of Australian gene technology policy
With regard to providing the requisite “organizational technology” for authentic community
involvement, the institutional framework of Australian gene technology policy is generally
ambiguous and open to interpretation. As explained below, the Gene Technology Act 2000
established the OGTR and three advisory committees, and detailed their respective functions.
The Act does not explicitly limit or prohibit community involvement; however, it can be inter-
preted such that the Gene Technology Regulator does not have to seriously encourage or con-
sider inputs from the community.
In Australia, the Gene Technology Act 2000 (Commonwealth of Australia, 2000) and its
supporting document, the Gene Technology Regulations 2001 (Commonwealth of Australia,
2001), provide the institutional basis for gene technology policy. It established the Gene
Technology Ministerial Council to “issue policy principles, policy guidelines and codes of
practice” (Commonwealth of Australia, 2001: 3). The Act also established the Office of the
Gene Technology Regulator (OGTR) to regulate gene technology in Australia, the Gene
Technology Technical Advisory Committee to provide scientific and technical advice to the
Ministerial Council and the Regulator, the Gene Technology Ethics Committee to provide
advice on ethical issues concerned with gene technology, policy principles and codes of con-
duct, and the Gene Technology Community Consultative Committee (GTCCC) to provide
advice to the Regulator and Ministerial Council on “matters of general concern,” policy prin-
ciples and codes of conduct.
In keeping with the requirements of Section 27 of the Act, the OGTR has established
means with which to keep the community informed about its activities and invite com-
ments from the community. These means include establishing the OGTR website (http://
www.ogtr.gov.au), where visitors can obtain information about the institutional framework,
the OGTR, the Gene Technology Ministerial Council and the gene technology advisory com-
mittees, monitoring and compliance, and applications for release of genetically modified
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(GM) organisms. From this website, visitors can also download organizational policies,
legislation, fact sheets, media releases and forms for making applications under the Act.
Interested parties can access a list of all GM organisms and products that have been
cleared for use, obtain communiqués of committee meetings and subscribe to a client reg-
ister to receive e-mailed updates of OGTR activities. There is also provision for the com-
munity to make submissions regarding the formulation of risk assessment and risk
management plans for the release of GM organisms and products. The OGTR also invites
comments in advertisements placed in the national newspaper, The Australian, regional
newspapers and the Commonwealth Government Notices Gazette. A minimum of 30 days
is allowed for feedback.
Formally, the institutional framework of Australian gene technology policy permits the
community to participate in policy formulation by requiring the OGTR to provide informa-
tion to the community and enabling the community to make submissions on applications for
the release of GM organisms and products. Furthermore, the GTCCC has been established to
give voice to the respective “interested publics.” Ostensibly, at least, the institutional frame-
work provides some scope for community involvement in biotechnology policy.
3. The Australian government Regulator and community involvement
While the formal institutional framework provides scope for community involvement, the
extent of involvement has been limited by the interpretation of the Gene Technology Act 2000.
The implications of the institutional framework for community involvement have gradually
become clearer: interested Australian citizens are effectively excluded from participating in
gene technology policy and treated as consumers of information, rather than as active citizens
capable of deliberating and contributing to public policy. In this third part of the article, we
present four institutional factors that undermine community involvement.
First, Schibeci et al. (2006) found that the influence of the GTCCC and the Gene
Technology Ethics Committee over biotechnology policy appears to be minimal compared
with that exerted by the Gene Technology Technical Advisory Committee. The Regulator
explicitly stated that advice would be or was sought from the Gene Technology Technical
Advisory Committee, but did not say whether the GTCCC and Gene Technology Ethics
Committee would be asked to contribute (OGTR, 2001, 2002a). While the Act states that the
Regulator must consult with the Gene Technology Technical Advisory Committee on all
matters pertaining to the risk assessment and risk management, it does not forbid the
Regulator from consulting with the GTCCC and the Gene Technology Ethics Committee on
these matters.
Second, further evidence of the low priority accorded the GTCCC is the length of time it
has taken to renew the membership of the Committee. In accordance with the GTCCC
Operating Procedures (OGTR, 2002b: 19), the appointments of the Committee members
expired after three years in October 2004. At the time of writing this article in March 2006,
however, no appointments to the GTCCC had been announced.
Third, the OGTR has continued to engage the community in a top-down manner that is
consistent with the “cognitive deficit” model. This has seen the Regulator (OGTR, 2003) dis-
miss opposition to GM products as being based on ignorance. In fact, little evidence can be
found that the OGTR is particularly interested in promoting community involvement or that
interested members of the community can actually influence policy outputs.
Fourth, the GTCCC website also does little to stimulate dialogue between the commu-
nity, the Committee and its secretariat (http://www.ogtr.gov.au/committee/gtccc.htm). As the
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primary interface between the GTCCC and the community, it is reasonable to expect its web-
site to be inviting and informative. Instead, the website originally described the role of the
Committee, identified and provided details about the Chair of the Committee and the other
members, and provided links to the Committee’s communiqués. There was no substantive
material published on the site about how the community may become involved in biotech-
nology policy. Specifically, there was no online discussion forum to which people could post
queries or discuss issues with Committee members, no list of forthcoming public meetings
that people could attend nor work produced by the GTCCC (other than the communiqués).
For example, it could have published the draft of its public consultation framework and
elicited feedback.
4. Review of the Gene Technology Act 2000
In May 2005, the Gene Technology Ministerial Council (Department of Health and
Ageing, 2005c) announced a review of the Gene Technology Act 2000 as required by
Section 194 of the Act. An independent (from the OGTR) panel of three was selected by
the Gene Technology Ministerial Council to review the Act. This review is considering the
scope of the Act (especially whether it should explicitly address the economic and social
impacts of gene technology), determining whether the Act is achieving its aims, investi-
gating the regulatory burden, examining the interface with other regulatory systems in
Australia, considering the effect of changing circumstances and, if necessary, will recom-
mend changes to the legislation (Department of Health and Ageing, 2005b). Over three
hundred submissions were received and used to formulate discussion questions for the
public hearings throughout the country (Department of Health and Ageing, 2005c). A
series of hearings were held in Canberra, Clare Valley, Adelaide, Perth, Brisbane,
Townsville, Narrabri, Sydney, Melbourne, Horsham, Hobart and Darwin from October to
December 2005.
The public hearing in Perth was held at the Duxton Hotel in Perth on 27 October 2005,
and was attended by one of the authors. It was also attended by 23 stakeholders and commu-
nity members (Department of Health and Ageing, 2006: 115–6), two of the three members of
the review panel and a secretariat member supporting the panel. The meeting was first
addressed by the Chair of the review panel, who set out the purpose of the review, and the
agenda and guidelines for the hearing.
Following this initial overview, three speakers from government and industry addressed
the audience. There were no speakers from environmental or consumer groups, hence, the
views put were fairly narrow in scope and set the theme for the very limited discussion
that followed. The first speaker was a representative from the OGTR secretariat, who sim-
ply outlined the institutional framework for gene technology in Australia. The second
speaker was a representative from an industry group, the Combined Bulk Handling Group.
This speaker claimed ambivalence towards the introduction of GM organisms and prod-
ucts, and was prepared to let individual farmers and the market decide whether the move
into GM crops should proceed. As far as the purity of non-GM crops was concerned, the
speaker claimed that the Combined Bulk Handling Group could guarantee the purity of the
product once it entered its internal supply chain. The third speaker from the Network of
Concerned Farmers (http://www.non-gm-farmers.com/) was somewhat skeptical of the
claims made by the previous speaker, especially those concerned with the possibility of
contamination of non-GM crops. The speaker was particularly concerned that liability for
maintaining the purity of the product resided with the farmer of non-GM products, not
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with those producing what the law regards as a contaminant, that is, the GM crop transferred
from one field to another.
The floor was then opened up to get feedback on points raised in the submissions; how-
ever, there was little discussion. One reason may be the relatively small number of people
who attended the hearing. This may be due, in part, to confusion over when the hearing was
to be held. The Department of Health and Ageing (2005a) website stated that the hearing
was to be held from 1 to 3 p.m. In fact, it was held between 10 a.m. and noon. While sub-
scribers to the OGTR’s notification list were aware of the correct time, people who consulted
the Department’s website may have turned up at the later time. The website was amended
soon after one of the authors notified the Department of the error.
The Chair also did little to stimulate discussion. In most cases, the Chair respectfully
thanked participants for their comments, asked if anyone had anything further to add and, if
not, moved on to the next point. Furthermore, there was little indication that the OGTR sec-
retariat or the review panel members were taking extensive notes of the proceedings. When
asked after the hearing about whether there were minutes taken of the hearing, the Chair
responded that they take occasional notes, if they hear something that they find interesting.
It is also possible that potential discussion by the lay public was quashed by the domi-
nance of stakeholders with specific interests over ordinary community. Carson and Martin
(2002: 106) have noted that “vested interests” can be a problem when choosing advisory pan-
els for citizens’ juries and it was evident that these groups were determined to make their
claims heard at this meeting. This is unfortunate, as some of these stakeholders had already
had an opportunity to speak privately to the review panel the previous day.
The site where the forum was held might also have shaken the confidence of those
members of the community who attended. The exclusive Duxton Hotel is centrally located in
the city and likely convenient for most of the stakeholders. Such a venue is not, however, the
most conducive for stimulating discussion among lay members of the community. Such sur-
roundings can be forbidding and not conducive to open discussion. Certainly, only two
members of the community who did not identify an affiliation felt sufficiently confident to
speak.
Our analysis of the Gene Technology Act 2000 and its application by the OGTR and the
Commonwealth Department of Health and Ageing has focused on community involvement in
gene technology policy. It is not intended to bring into question the competencies of the
agency and department in applying the Act as it stands. Instead, it seeks to explain how the
content of the Act, a particular reading of the Act and attitudes towards community involve-
ment have effectively excluded community members (as distinct from stakeholders with
vested interests) from participating in biotechnology policy.
5. Review of the Regulator by the Australian National Audit Office
The impact of the institutional design on community involvement in biotechnology was par-
ticularly evident in the audit of the OGTR undertaken by the Australian National Audit Office
(ANAO) in 2004–5. In its final report, the ANAO (2005: 28) stated that the OGTR was
audited for four reasons. First, an audit was warranted because the OGTR plays a key role
with respect to “public health and environmental matters.” Second, the OGTR had not been
previously audited. Third, an audit was a necessary response to the public interest in gene
technology, “particularly over field trials of genetically modified (GM) agricultural crops.”
Fourth, the audit was expected to contribute to the statutory review of the gene technology
regulatory framework that was due to commence in mid-2005.
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While the ANAO (2005: 20) was generally satisfied that the OGTR was managed effec-
tively and efficiently and that the sector was being regulated in accordance with the Gene
Technology Act 2000, the ANAO (2005: 101) expressed concern that the OGTR took so long
to report to Parliament. Although the OGTR is not required to release its quarterly reports by
a particular time, the ANAO noted that they “are not usually published until at least the end
of the following quarter.” Hence, even in terms of alleviating cognitive deficit, the OGTR had
not provided the community with information as quickly as it ought.
The ANAO paid little attention, however, to the OGTR’s performance in promoting com-
munity involvement in biotechnology and, instead, followed accepted auditing practice and
concerned itself primarily with the systems and procedures established by the OGTR to man-
age the assessment of applications and compliance with its orders. Nevertheless, the ANAO
(2005: 29) implicitly acknowledged that it could assess other “selected aspects” of the work
undertaken by the OGTR and determine whether these were managed “efficiently and effec-
tively.” In other words, it could also have commented on the management and performance
of the three committees, including the GTCCC. For example, it might have noted that while
a communiqué of each GTCCC is supposed to be available to the lay public on the OGTR
website “within 48 hours &...; where possible” (OGTR, 2002b: 8), these usually became
available just before the following meeting. Instead, the report mentions the GTCCC fleet-
ingly with respect to its formal functions.
6. Looking ahead: reviewing the Gene Technology Act 2000
As we explained above, an independent review of the operation of the Gene Technology Act
2000 and of the OGTR began in mid-2005. If the independent review panel is interested in
achieving the authentic community involvement in gene technology policy which is permit-
ted in the Act, then it needs to establish appropriate mechanisms. The design of these mech-
anisms needs to provide clear and precise instructions that require the OGTR, the GTCCC
and the Gene Technology Ethics Committee to engage with the wider community and “inter-
ested publics.” In this section, we make five recommendations that will enhance genuine com-
munity involvement in Australian biotechnology policy.
Adopt a broader concept of risk
A broader concept of risk needs to be adopted to accommodate the broad range of interests
and concerns within the community. Currently, the concept of risk in the Act is narrowly inter-
preted to pertain solely to matters pertaining to health and safety of people and the environ-
ment. In fact, Section 51 of the Act (Commonwealth of Australia, 2000) states that
(1) In preparing the risk assessment in relation to the dealings proposed to be authorised
by the licence, the Regulator must take into account the following:
(a) the risks posed by those dealings, including any risks to the health and safety of
people or risks to the environment, having regard to the matters mentioned in paragraphs
49(2)(a) to (f).
There is nothing in the section that precludes the Regulator from adopting a broader concept
of risk to include, for example, economic issues. The Act simply states that the Regulator’s
assessments must include risks associated with human health and safety and the environ-
ment. It may also include other risks. If these others risks are precluded from the Regulator’s
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assessments, then many people in the community are effectively excluded from participating
in gene technology policy. Thus, we recommend that the Act be revised to incorporate an
explicit statement that the Regulator must take into account social and economic risks.
Institute gene technology committees of equal standing
To facilitate genuine community involvement, the Gene Technology Act 2000 needs to be
amended so that the GTCCC and Gene Technology Ethics Committee have the same stand-
ing as the Gene Technology Technical Advisory Committee. A statutory requirement would
require the Regulator to consult with the GTCCC and Gene Technology Ethics Committee on
each application for a license to release GM organisms and products into the environment, as
well as for approval for research operations in contained environments. This would also be
necessary for a thorough assessment of the risks associated with applications. Although
members of the Gene Technology Technical Advisory Committee are well qualified to assess
technical risks, they may be less able to address social and economic risks.
While some may not support the likely delay of approval of applications, it may actually
reduce general political opposition to GM organisms and products and the time spent seeking
the support of political leaders. This is evidenced, for example, by the current moratoria on
the open release of GM canola in all Australian states. It has undoubtedly delayed the devel-
opment of the GM canola industry in Australia much more than could any ethics or commu-
nity-oriented committee. Moreover, the Regulator would only be obliged to consider the
recommendations of the Gene Technology Ethics Committee and the GTCCC and justify rea-
sons for accepting or rejecting these recommendations. The Regulator would retain responsi-
bility for the final decision, as is now the case.
Embrace disagreement and conflict
The operating procedures of the respective committees must be relaxed to allow members to
communicate with the wider community about committee matters. This is not to say that com-
mittee members should betray confidences: rather that people should be made aware that the
committee members represent a wide range of views, that views similar to their own are being
expressed in committee meetings, that there are differences of opinions, and that the com-
mittees are not rubber stamps for government policy.
To this end, the OGTR and the overseeing Gene Technology Ministerial Council need to
accept that disagreement and conflict are integral to policy areas characterized by great uncer-
tainty and risk: this is part and parcel of living in a pluralistic democracy. Attempts to dampen
down the social and economic dimensions of gene technology will only serve to heighten cur-
rent concerns and lead people to question the legitimacy of policy decisions. The cases of air
pollution (Bush et al., 2001) and bovine spongiform encephalopathy (Jasanoff, 1997) in the
United Kingdom highlight the backlash against governments that ensues if governments
endeavor to “cover up” what the community perceives to be the truth. Moreover, such cases
reinforce views that governments cannot be trusted and may promote a general hostility
towards experts, science and technology.
Use the Web effectively
Although the OGTR uses its website to inform interested publics of forthcoming applications
and the regulation of gene technology, it needs to make greater use of the Web to make public
its deliberations and those of the committees, as well as encourage community involvement
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in biotechnology policy. As explained above, the communiqués of the GTCCC’s meetings were
not entirely revealing as to why the Committee came to particular conclusions. Furthermore,
it is not clear what the Committee actually achieved in the first three years. It is not being sug-
gested that the Committee did nothing or achieved nothing, but it would be more evident if
working papers, even drafts, were published on the OGTR website. To these might be added
the agenda of all Committee meetings.
Another obvious way to generate community involvement is through a discussion forum.
People could submit queries to the OGTR and Committee secretariats, as well as to individ-
ual Committee members. They could also engage with other community-minded individuals
on gene technology issues. While this would be time consuming for the secretariats and may
necessitate the expansion of the OGTR, such a forum could become a hub for information
exchange that policymakers could access.
Develop a framework of community involvement
The OGTR must establish a framework to determine the appropriate mechanism for commu-
nity involvement in each case and evaluate the effectiveness of each exercise. If the Regulator
required expert advice on a particularly esoteric technical matter that went beyond even the
scope of the Gene Technology Technical Advisory Committee, then it would be more appro-
priate to establish an expert panel than a citizens’ jury. If, on the other hand, there was great
uncertainty and conjecture about an issue that had entered the public domain, then a citizens’
jury or consensus conference may be more applicable. Research has commenced in this area
and the OGTR and the GTCCC would do well to consider this literature (Citizens and Civics
Unit, 2003; Rowe and Frewer, 2005, 2004).
It might also be worth considering incorporating into the Gene Technology Act 2000 a sec-
tion pertaining specifically to community involvement in decision-making. Here, Norway’s
Environmental Information Act could serve as a template. Section 20 of the Environmental
Information Act requires government agencies to “make provision” for community involve-
ment in the formulation of environmental plans, legislation and policies and have “real oppor-
tunities to influence the decisions that are made” (Ministry of the Environment, 2003). Most
importantly, “it shall be clear how the requirements of this provision have been met, and how
comments and other input from the public have been evaluated.” Many participants and other
interested people in the community will remain skeptical until the policy process is fully trans-
parent and they can see why proposals/suggestions have been accepted or rejected. Only then
will policy decisions be widely regarded as legitimate.
7. Conclusion
In this article, we returned to the case of community involvement in Australian biotechnology
policy assessed earlier by Dietrich and Schibeci (2003) and argued that it has been under-
mined, at least in part, by institutional design. We described the institutional framework that
has been established to regulate gene technology, the legislation on which the framework is
based and the roles of the constituent bodies. In particular, the Office of the Gene Technology
Regulator (OGTR) and the Gene Technology Community Consultative Committee (GTCCC)
were identified as having the most potential to initiate and further community interest and par-
ticipation in gene technology policy. We then explained how the Gene Technology Act 2000
relegates the GTCCC and the Gene Technology Ethics Committee and hence, community
involvement, to a secondary position behind the Gene Technology Technical Advisory
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Committee. We also explained how the GTCCC has been hamstrung by restrictive operating
procedures designed to depoliticize biotechnology policy, but also serve to obscure the oper-
ations of the Committee. Meanwhile, the OGTR provides considerable material in keeping
with the cognitive deficit model and does little to facilitate a dialogue with the community.
The general reluctance to involve the community in biotechnology policy was shown to be
particularly evident during a public hearing as part of the review of the Gene Technology Act
2000. Finally, we proposed a series of changes to the institutional framework that we feel will
open up Australian biotechnology policy to the wider community.
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